NetworkNewsBreaks

TuesdayMar 25, 2025 9:30 am

NetworkNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Present at Jones Las Vegas Technology and Innovation Conference

Clene (NASDAQ: CLNN), a clinical-stage biopharmaceutical company advancing treatments for neurodegenerative diseases such as ALS and MS, will participate in the Jones Las Vegas Technology and Innovation Conference on April 8–9, 2025. Held at The Venetian Resort, the event will feature one-on-one meetings, panels, and networking with institutional investors. Clene CEO Rob Etherington will represent the company as it continues to highlight progress across its therapeutic pipeline. The conference is hosted by JonesTrading with marketing support from B2i Digital, Inc. To view the full press release, visit https://nnw.fm/Nx11v About Clene Inc. Clene (along with its subsidiaries, “Clene”) and its wholly owned…

Continue Reading

TuesdayMar 25, 2025 9:20 am

NetworkNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Taps IBN to Lead Corporate Communications Strategy

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company targeting rare diseases, has selected IBN to manage its corporate communications and investor outreach. Soligenix is advancing late-stage clinical programs through its oncology and inflammation-focused Specialized BioTherapeutics segment and its Public Health Solutions division, which develops vaccines for biothreats such as ricin, Ebola, and Marburg. With support from roughly $60 million in non-dilutive funding and a pipeline that includes multiple orphan and fast-track designations, the company is preparing for potential regulatory approvals. IBN will amplify Soligenix’s message through its expansive media and investor network. To view the full article, visit https://nnw.fm/IOhxj About Soligenix…

Continue Reading

TuesdayMar 25, 2025 9:00 am

NetworkNewsBreaks – Centri Capital Conference to Showcase the Future of Capital Markets

Centri Business Consulting, LLC, one of the industry's fastest-growing and most respected accounting and advisory firms, is set to host its Centri Capital Conference. Slated to take place at Nasdaq in New York City on April 22, the event will bring together key players from the capital markets ecosystem, including investment bankers, private equity investors and venture capitalists. The conference will feature dynamic presentations from companies spanning rapidly growing sectors such as healthcare, life sciences and technology, as well as thought-provoking panel discussions on hot topics including blockchain, AI, IPO trends, and market disruptors. Designed as a platform for networking…

Continue Reading

MondayMar 24, 2025 11:00 am

NetworkNewsBreaks – Thumzup Media Corp. (NASDAQ: TZUP) Reports Insider Stock Purchases and Accelerated Buybacks

Thumzup (NASDAQ: TZUP), an emerging player in social media branding and programmatic marketing, reported that company insiders acquired approximately $60,381 in common stock during the March 2025 trading window, following $62,000 in purchases in Dec. 2024. Cumulatively, insiders have invested over $740,000 in the company since inception. Thumzup also repurchased about $216,000 worth of stock in the past three trading days under its $1 million buyback program, signaling continued confidence in its growth trajectory. The company recently surpassed 700 advertisers and maintains a CAGR above 200 percent.  To view the full press release, visit https://nnw.fm/Ec6A7  About Thumzup®  Thumzup Media Corporation…

Continue Reading

MondayMar 24, 2025 10:43 am

NetworkNewsBreaks – Clene Inc. (NASDAQ: CLNN) Plans 2025 NDA Submission Following Positive ALS Trial Data 

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company, reported a full-year 2024 net loss of $39.4 million, or $5.67 per share, compared to a loss of $49.5 million in 2023. Revenue remained limited, but Clene highlighted regulatory progress and survival data supporting CNM-Au8, its gold nanocrystal suspension for ALS. The company expects to meet with the FDA in Q2 2025 to finalize analysis plans for biomarker data, with a potential accelerated NDA submission in the second half of 2025. Clene ended the year with $12.2 million in cash and expects to begin enrollment for its confirmatory Phase 3 RESTORE-ALS trial in…

Continue Reading

MondayMar 24, 2025 9:47 am

NetworkNewsBreaks – Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) Secures Actinium-225 Supply Agreement with Eckert & Ziegler to Support Expanding Pipeline 

Actinium Pharmaceuticals (NYSE AMERICAN: ATNM), a leader in targeted radiotherapies, announced a supply agreement with Eckert & Ziegler for Actinium-225 (Ac-225) to support development of its lead candidate Actimab-A and other radiotherapy programs. The agreement ensures access to high-quality Ac-225 for both U.S. and international clinical trials. Actimab-A, an Ac-225-based agent targeting CD33, is being advanced into pivotal Phase 2/3 trials for relapsed/refractory acute myeloid leukemia and early-stage studies in combination with checkpoint inhibitors for solid tumors including head and neck and non-small cell lung cancers. The partnership strengthens Actinium’s ability to scale development and meet global demand for targeted…

Continue Reading

MondayMar 24, 2025 9:20 am

NetworkNewsBreaks – Brera Holdings PLC (NASDAQ: BREA) Highlights Juve Stabia Academy as Key Youth Football Investment

Brera Holdings (NASDAQ: BREA), an Ireland-based international holding company focused on multi-club ownership, spotlighted the Juve Stabia Academy for its role in developing elite football talent in the Naples Metropolitan Area. The investment reflects Brera’s strategy to support grassroots football and create a global network of academies. Juve Stabia has a history of producing top-tier talent, including Luigi Vitale and Antonio Donnarumma, and aligns with Brera’s mission to strengthen football ecosystems and expand pathways for emerging players worldwide. To view the full press release, visit https://nnw.fm/pv5ES About Brera Holdings PLC Brera Holdings PLC is focused on expanding its social impact…

Continue Reading

FridayMar 21, 2025 3:16 pm

NetworkNewsBreaks – Upstream at the Forefront of the Shift Toward Expanded Trading 

Upstream published a blog today that discussed challenges faced by legacy stock exchanges transitioning to 24/5 trading, outlining obstacles such as outdated infrastructure, regulatory hurdles, operational constraints for brokers and clearing firms, liquidity fragmentation, and cybersecurity risks. Significant upgrades are needed for traditional exchanges to support real-time settlement and extended trading hours. On the other hand, blockchain-powered platforms like Upstream are designed to overcome these hurdles. Upstream enables 20/7, peer-to-peer trading, liquidity, a fair trading ecosystem, and biometric authentication and smart contracts to ensure transparency and security. Upstream believes continuous market access is the future and is committed to driving…

Continue Reading

FridayMar 21, 2025 1:52 pm

NetworkNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI): Poised in the Future of Oncology with Cutting-Edge Treatments

Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage biotechnology company at the forefront of research and development of innovative treatments in the field of immuno-oncology. With cancer being the second leading cause of death globally, the company focuses on harnessing antitumor virotherapies and patented technologies designed to protect and potentiate the virotherapy during administration to combat cancer more effectively and with fewer side effects. The company’s approach includes a systemic platform using extracellular enveloped viruses and an intratumoral platform utilizing stem cells to protect the therapy from the body’s immune system during administration. Calidi’s pipeline includes promising therapies such as RTNova,…

Continue Reading

FridayMar 21, 2025 12:24 pm

NetworkNewsBreaks – Clene Inc. (NASDAQ: CLNN) Unveils Progress on CNM-Au8(R), Eyes Potential Fast-Track FDA Approval

Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), is actively advancing its lead drug candidate, CNM-Au8®. The company presented its progress at two key investor events this month, including the Q1 Virtual Investor Summit and the 37th Annual Roth Conference. At both events, Clene’s management discussed the latest achievements with CNM-Au8, a gold nanocrystal-based oral suspension that targets mitochondrial dysfunction and promotes neuronal health. The drug has shown promising results in…

Continue Reading